CorMedix (NASDAQ:CRMD) reported a significant return to profitability for the fourth quarter on Thursday, as the commercial rollout of its lead product, DefenCath, gained momentum alongside contributions from its newly acquired Melinta Therapeutics portfolio.
The Berkeley Heights, New Jersey-based biopharmaceutical company posted a net income of $14 million, or 16 cents per share.
On an adjusted basis, excluding one-time tax expenses and integration costs, earnings reached 61 cents per share.
Quarterly revenue surged to $128.6 million, driven by $91.2 million in DefenCath sales to outpatient dialysis providers and $37.4 million from the Melinta anti-infective business.
For the full year, CorMedix reported a profit of $163.1 million, or $2.04 per share, a sharp reversal from the $17.9 million loss recorded in 2024.
Total annual revenue reached $311.7 million.
Looking ahead, the company reaffirmed its 2026 revenue guidance of $300 million to $320 million, noting a transition in Medicare reimbursement for DefenCath expected in the second half of the year.